DZ3484A1 - Compositions pharmaceutiques comprenant un agoniste des recepteurs nmda - Google Patents

Compositions pharmaceutiques comprenant un agoniste des recepteurs nmda

Info

Publication number
DZ3484A1
DZ3484A1 DZ013484A DZ013484A DZ3484A1 DZ 3484 A1 DZ3484 A1 DZ 3484A1 DZ 013484 A DZ013484 A DZ 013484A DZ 013484 A DZ013484 A DZ 013484A DZ 3484 A1 DZ3484 A1 DZ 3484A1
Authority
DZ
Algeria
Prior art keywords
pharmaceutical compositions
receptor agonist
nmda receptor
nmda
agonist
Prior art date
Application number
DZ013484A
Other languages
English (en)
Inventor
Jinyang Hong
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DZ3484A1 publication Critical patent/DZ3484A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DZ013484A 2000-12-13 2001-12-05 Compositions pharmaceutiques comprenant un agoniste des recepteurs nmda DZ3484A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25537200P 2000-12-13 2000-12-13
PCT/IB2001/002359 WO2002047685A2 (fr) 2000-12-13 2001-12-05 Compositions pharmaceutiques de l'agoniste du recepteur nmda

Publications (1)

Publication Number Publication Date
DZ3484A1 true DZ3484A1 (fr) 2002-06-20

Family

ID=22968017

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ013484A DZ3484A1 (fr) 2000-12-13 2001-12-05 Compositions pharmaceutiques comprenant un agoniste des recepteurs nmda

Country Status (42)

Country Link
US (2) US6635270B2 (fr)
EP (1) EP1347760B1 (fr)
JP (1) JP2004515529A (fr)
KR (1) KR100533407B1 (fr)
CN (1) CN1273135C (fr)
AP (1) AP1235A (fr)
AR (1) AR035607A1 (fr)
AT (1) ATE296629T1 (fr)
AU (2) AU2002218454B2 (fr)
BG (1) BG107788A (fr)
BR (1) BR0116085A (fr)
CA (1) CA2431172A1 (fr)
CZ (1) CZ20031543A3 (fr)
DE (1) DE60111265T2 (fr)
DO (1) DOP2001000300A (fr)
DZ (1) DZ3484A1 (fr)
EA (1) EA006489B1 (fr)
EC (1) ECSP034655A (fr)
EE (1) EE200300284A (fr)
ES (1) ES2239648T3 (fr)
GE (1) GEP20053568B (fr)
HK (1) HK1059575A1 (fr)
HR (1) HRP20030473A2 (fr)
HU (1) HUP0400645A2 (fr)
IL (1) IL155810A0 (fr)
IS (1) IS6811A (fr)
MA (1) MA26970A1 (fr)
MX (1) MXPA03005257A (fr)
NO (1) NO20032678D0 (fr)
NZ (1) NZ525742A (fr)
OA (1) OA12414A (fr)
PA (1) PA8534901A1 (fr)
PE (1) PE20020710A1 (fr)
PL (1) PL362080A1 (fr)
PT (1) PT1347760E (fr)
SK (1) SK6982003A3 (fr)
TN (1) TNSN01173A1 (fr)
UA (1) UA73619C2 (fr)
UY (1) UY27068A1 (fr)
WO (1) WO2002047685A2 (fr)
YU (1) YU41103A (fr)
ZA (1) ZA200303892B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1615646T4 (da) 2003-04-08 2022-10-10 Progenics Pharm Inc Farmaceutiske formuleringer, der indeholder methylnaltrexon
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
AR063984A1 (es) * 2006-11-28 2009-03-04 Wyeth Corp Metabolitos de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina, metodos de preparacion, su uso en la fabricacion de medicamentos para el tratamiento de trastornos relacionados con 5-ht1a, composicion farmaceutica que los comprende, compuestos radioetiquetados derivado
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
CN101317844B (zh) * 2007-06-08 2010-11-17 章劲夫 化合物(+)-5-甲基-10，11-二氢-5H-二苯并〔a，d〕环庚烯-5，10-亚胺在制备避孕药物中的应用
BRPI0918868B8 (pt) 2008-09-18 2021-05-25 Naurex Inc compostos moduladores do receptor de nmda e composições compreendendo os mesmos
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
CA2789331C (fr) 2010-02-11 2017-11-07 Northwestern University Modulateurs des recepteurs nmda a structure secondaire stabilisee et leurs utilisations
CN102586243A (zh) * 2012-03-08 2012-07-18 中国人民解放军军事医学科学院放射与辐射医学研究所 一种预防电磁辐射致脑损伤的标志物
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
MX2015009773A (es) 2013-01-29 2016-08-05 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2015009772A (es) 2013-01-29 2016-05-31 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
HRP20221545T1 (hr) 2013-01-29 2023-03-03 Aptinyx Inc. Spiro-lactam nmda receptorski modulatori i njihove uporabe
US9738650B2 (en) 2013-01-29 2017-08-22 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
AU2014212501A1 (en) 2013-01-29 2015-07-30 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
MX2016008369A (es) 2013-12-23 2016-12-15 Samyang Biopharmaceuticals Composicion farmaceutica que incluye palonosetron.
WO2017201285A1 (fr) 2016-05-19 2017-11-23 Aptinyx Inc. Modulateurs spirolactames des récepteurs nmda et leurs utilisations
EP3458458B1 (fr) 2016-05-19 2020-11-04 Aptinyx Inc. Modulateurs de récepteurs nmda de spiro-lactame et utilisations associées
EP3490974B1 (fr) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Modulateurs nmda a base de spirolactams et leur methode d'utilisation
CN109937204B (zh) 2016-08-01 2022-11-25 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
EA201990428A1 (ru) 2016-08-01 2019-08-30 Аптиникс Инк. Спиролактамовые модуляторы nmda-рецептора и их применение
CA3031562A1 (fr) 2016-08-01 2018-02-08 Aptinyx Inc. Modulateurs spiro-lactames et bis-spiro-lactames des recepteurs nmda et leurs utilisations
US11370790B2 (en) 2016-08-01 2022-06-28 Aptinyx Inc. Spiro-lactam NMDA modulators and methods of using same
EP3746447A1 (fr) 2018-01-31 2020-12-09 Aptinyx Inc. Spiro-lactame modulateur des récepteurs nmda et leurs utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) * 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
US5710168A (en) 1991-10-23 1998-01-20 Pfizer Inc. 2-piperidino-1-alkanol derivatives as neuroprotective agents
CN1198739A (zh) * 1995-08-11 1998-11-11 美国辉瑞有限公司 (1s,2s)－1－(4－羟基苯基)－2－(4－羟基－4－苯基哌啶－1－基)－1－丙醇甲磺酸盐三水合物
TW450807B (en) * 1995-09-15 2001-08-21 Pfizer Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents

Also Published As

Publication number Publication date
GEP20053568B (en) 2005-07-11
DE60111265D1 (de) 2005-07-07
AU2002218454B2 (en) 2005-10-27
PE20020710A1 (es) 2002-08-09
DOP2001000300A (es) 2002-05-30
NO20032678L (no) 2003-06-12
MA26970A1 (fr) 2004-12-20
JP2004515529A (ja) 2004-05-27
SK6982003A3 (en) 2004-08-03
US20020111366A1 (en) 2002-08-15
MXPA03005257A (es) 2003-09-25
WO2002047685A2 (fr) 2002-06-20
WO2002047685A3 (fr) 2002-08-15
CN1273135C (zh) 2006-09-06
KR100533407B1 (ko) 2005-12-02
DE60111265T2 (de) 2006-05-04
PL362080A1 (en) 2004-10-18
OA12414A (en) 2006-04-18
EA006489B1 (ru) 2005-12-29
IL155810A0 (en) 2003-12-23
BG107788A (bg) 2004-01-30
US20040039022A1 (en) 2004-02-26
AP1235A (en) 2004-01-06
EP1347760B1 (fr) 2005-06-01
EA200300514A1 (ru) 2003-10-30
ZA200303892B (en) 2004-05-20
CZ20031543A3 (cs) 2004-06-16
PA8534901A1 (es) 2002-08-26
NO20032678D0 (no) 2003-06-12
IS6811A (is) 2003-05-08
US6635270B2 (en) 2003-10-21
AR035607A1 (es) 2004-06-16
BR0116085A (pt) 2003-12-23
ECSP034655A (es) 2003-07-25
PT1347760E (pt) 2005-09-30
UY27068A1 (es) 2002-07-31
EP1347760A2 (fr) 2003-10-01
CA2431172A1 (fr) 2002-06-20
TNSN01173A1 (fr) 2005-11-10
NZ525742A (en) 2005-07-29
EE200300284A (et) 2003-10-15
AP2001002376A0 (en) 2001-12-31
HRP20030473A2 (en) 2005-04-30
CN1479617A (zh) 2004-03-03
ES2239648T3 (es) 2005-10-01
YU41103A (sh) 2006-05-25
ATE296629T1 (de) 2005-06-15
UA73619C2 (en) 2005-08-15
HUP0400645A2 (hu) 2004-06-28
HK1059575A1 (en) 2004-07-09
AU1845402A (en) 2002-06-24
KR20030070060A (ko) 2003-08-27

Similar Documents

Publication Publication Date Title
DZ3484A1 (fr) Compositions pharmaceutiques comprenant un agoniste des recepteurs nmda
FR2804025B1 (fr) Compositions pharmaceutiques stabilisees
NO20023728L (no) Manipuleringsresistente, orale opioidagonistformuleringer
ITTO20010005A0 (it) Formulazione farmaceutica.
MXPA02002546A (es) Composiciones farmaceuticas que comprenden un receptor agonista o antagonista de la adenosina.
PL365377A1 (en) Amide derivatives as nmda receptor antagonists
AP2004003055A0 (en) Platinum derivative pharmaceutical formulations.
HUP0301777A3 (en) Aniline-derived ligands for the thyroid receptor, pharmaceutical compositions comprising thereof and their use
EG24194A (en) 5ht-a-partial agonist pharmaceutical compositions
DE60122495D1 (de) TRANS-N-i4-(4-HYDROXYPHENYL)CYCLOHEXYLö-3-PHENYLPROPIONAMID ALS SUBTYP-SELEKTIVER NMDA REZEPTOR ANTAGONIST
DK1068202T3 (da) 1-(-heteroarylpropyl- eller -prop-2-enyl)-4benzylpipderidiner som NMDA-receptor-antagonister
HUP0300419A3 (en) Estrogen agonist/antagonist metabolites, pharmaceutical compositions containing them and their use
FR2802423B1 (fr) Compositions pharmaceutiques
ATE291900T1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
FR2792529B1 (fr) Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
AU2001286409A1 (en) N-methyl-d-aspartate receptor antagonists
FR2797444B1 (fr) Compositions pharmaceutiques comprenant des 4-quinolones
MA26604A1 (fr) Compositions pharmaceutiques.
HUP0200057A2 (en) Dopamine d1 receptor agonist compounds, pharmaceutical compositions containing them and their use
SI1347760T1 (en) Nmda receptor agonist pharmaceutical compositions
DK1200400T3 (da) Substituerede pyrrolidin-2,3,4-trion derivater, der er anvendelse som NMDA-receptorantagonister
DK1450770T3 (da) Farmaceutisk præparat, der omfatter en 5HT1-receptoragonist
SE9901967D0 (sv) New solid dosage formulation